The use of prostacyclin in the separation from plasma and washing of human platelets.
A new method for the separation from plasma and washing of human platelets is described. The use of prostacyclin (PGI2) throughout the procedure prevents the activation of platelets. The method allows a 60-70% yield of platelets from PRP. The platelet sensitivity to ADP, collagen, adrenaline, arachidonic acid and thrombin is the same as in PRP. The platelet suspension is stable for long periods and the reactivity to aggregating agents remains unchanged for periods greater than 48 h when platelets are stored at 4 degrees C.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology; D002469:Cell Separation / Q000379:methods*; D003094:Collagen / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000494:pharmacology; D011464:Epoprostenol; D005260:Female; D005340:Fibrinogen / Q000494:pharmacology; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D010983:Plateletpheresis / Q000379:methods*; D011453:Prostaglandins; D013997:Time Factors
D001095:Arachidonic Acids; D011453:Prostaglandins; D016718:Arachidonic Acid; D000244:Adenosine Diphosphate; D005340:Fibrinogen; D003094:Collagen; D011464:Epoprostenol; D007213:Indomethacin; D004837:Epinephrine